Home › Free Stock Grades › IMNM
Immunome, Inc. (IMNM) Stock Grade
IMNM · Healthcare
C
Market Cap
$2.1B
P/E Ratio
—
Revenue Growth (YoY)
-23.2%
Net Margin
-3060.0%
Return on Equity
—
Dividend Yield
None
About Immunome, Inc.'s fundamentals
Immunome is a biotechnology company with a market capitalization of $2.1 billion that reported a significant net loss in its latest annual statement, resulting in a net margin of -3060.0%. The company experienced revenue decline of 23.2% year-over-year, indicating contraction in its top-line performance. As a pre-profitability biotech firm, traditional valuation metrics like P/E ratio and return on equity are not applicable, and the company does not currently pay dividends.